| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Otenabant free base (also known as CP-945,598) is a novel, potent and highly selective cannabinoid receptor CB1 antagonist with Ki of 0.7 nM, it exhibits >10,000-fold greater selectivity against human CB2 receptor. Otenabant is an authorized medication created by Pfizer to treat obesity; however, because of issues encountered during the clinical use of the comparable medication rimonabant, the development of this medication has been halted.
| Targets |
CB1 ( Ki = 0.7 nM )
|
||
|---|---|---|---|
| ln Vitro |
|
||
| ln Vivo |
|
||
| Enzyme Assay |
Membranes are made from CHOK1 cells that have had the human CB-1 receptor cDNA transfected into them permanently. The GTPγ [35S] binding assays are carried out in duplicate in a 96-well FlashPlate format using 100 pM GTPγ [35S] and 10μg membrane per well in an assay buffer consisting of 50 mM Tris HCl, pH 7.4, 3 mM MgCl2, pH 7.4, 10 mM MgCl2, 20 mM EGTA, 100 mM NaCl, 30 µM GDP, 0.1% bovine serum albumin, and the protease inhibitors 100 μg/mL bacitracin, 100 μg/mL benzamidine, 5 μg/mL aprotinin, and 5 μg/mL leupeptin. After 10 minutes of incubation with escalating antagonist concentrations (10-10 M to 10-5 M), the assay mix is challenged with the cannabinoid agonist CP-55,940 (10 μM). Assays are run for one hour at 30°C. After that, the FlashPlates are centrifuged for 10 minutes at 2000 g. Following that, a Wallac Microbeta is used to quantify the stimulation of GTPγ [35S] binding. The EC50 is calculated with GraphPad Prism. Inverse agonism is measured in the absence of agonist.
|
||
| Cell Assay |
For the DIO weight loss study, male 14-week-old C57/Bl6/6J mice that have been fed a high-fat diet (45% kcal from fat) for six weeks are chosen. The animals' body weights differ by at least five standard deviations from the mean body weight of age-matched, chow-fed control animals. Mice live alone in enclosures. All animals have an initial weight of 38.9±0.5 g on average. Mice are randomly allocated to treatment groups on day 0 (n = 10 per group). Over the course of ten days, mice are given daily doses of vehicle or 10 mg/kg (p.o.) CP-945,598. This begins roughly thirty minutes prior to the start of the 12-hour dark cycle. Food consumption and BW are tracked every day. For daily and cumulative FI and cumulative BW measurements, analysis of variance and comparison of means are computed. It is deemed statistically significant when P < 0.05.
|
||
| Animal Protocol |
|
||
| References |
|
||
| Additional Infomation |
Otenabant has been investigated for the treatment of Obesity.
Mechanism of Action Pre-clinical and clinical trial data suggest that CB-1 antagonists may have favorable effects on glucose metabolism in patients with type 2 diabetes and may also be an effective therapy for the treatment of obesity. |
| Molecular Formula |
C25H25CL2N7O
|
|---|---|
| Molecular Weight |
510.4183
|
| Exact Mass |
509.15
|
| Elemental Analysis |
C, 58.83; H, 4.94; Cl, 13.89; N, 19.21; O, 3.13
|
| CAS # |
686344-29-6
|
| Related CAS # |
Otenabant Hydrochloride; 686347-12-6
|
| PubChem CID |
10052040
|
| Appearance |
White to off-white solid powder
|
| Density |
1.46
|
| Boiling Point |
757.891ºC at 760 mmHg
|
| LogP |
5.379
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
35
|
| Complexity |
729
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClC1=C([H])C([H])=C([H])C([H])=C1C1=NC2=C(N=C([H])N=C2N2C([H])([H])C([H])([H])C(C(N([H])[H])=O)(C([H])([H])C2([H])[H])N([H])C([H])([H])C([H])([H])[H])N1C1C([H])=C([H])C(=C([H])C=1[H])Cl
|
| InChi Key |
UNAZAADNBYXMIV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C25H25Cl2N7O/c1-2-31-25(24(28)35)11-13-33(14-12-25)22-20-23(30-15-29-22)34(17-9-7-16(26)8-10-17)21(32-20)18-5-3-4-6-19(18)27/h3-10,15,31H,2,11-14H2,1H3,(H2,28,35)
|
| Chemical Name |
1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)purin-6-yl]-4-(ethylamino)piperidine-4-carboxamide
|
| Synonyms |
CP945598; CP-945598; CP 945598; CP945,598; CP-945,598; CP 945,598; Otenabant
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~195.9 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 3 mg/mL (5.88 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 30.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 3 mg/mL (5.88 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 30.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 3 mg/mL (5.88 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9592 mL | 9.7959 mL | 19.5917 mL | |
| 5 mM | 0.3918 mL | 1.9592 mL | 3.9183 mL | |
| 10 mM | 0.1959 mL | 0.9796 mL | 1.9592 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT00645463 | Completed | Drug: CP-945,598 | Obesity | Pfizer | March 2007 | Phase 1 |
| NCT00644839 | Completed | Drug: CP-945,598 | Obesity | Pfizer | April 2008 | Phase 1 |
| NCT00645216 | Completed | Drug: CP-945,598 | Obesity | Pfizer | June 2007 | Phase 1 |
| NCT00134199 | Completed | Drug: CP-945,598 Drug: sibutramine |
Obesity | Pfizer | March 2005 | Phase 2 Phase 3 |
| NCT00706537 | Completed | Drug: Active treatment Drug: Placebo |
Non-Alcoholic Steatohepatitis (NASH) |
Pfizer | July 2008 | Phase 1 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
